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Introduction: Platelet activation is related to the psychopathology of major depression. We attempted to search and
identify protein biomarkers from the platelets of patients with major depression. High resolution two-dimensional
Differential Gel Electrophoresis (2D-DIGE), the matrix-assisted laser desorption/ionization time-of-flight mass
spectrometry (MALDI-TOF MS), Western blot, and bioinformatic tools were applied to examine the platelet proteins of
10 patients with major depression and 10 healthy controls.
Results: The levels of 8 proteins were significantly different between the patients with major depression in the acute
phase and healthy controls. The levels of protein disulfide-isomerase A3 (PDIA3) and F-actin-capping protein subunit
beta (CAPZB) were higher in patients with major depression than in healthy controls. The levels of fibrinogen beta chain
(FIBB), fibrinogen gamma chain (FIBG), retinoic acid receptor beta (RARB), glutathione peroxidase 1 (GPX1), SH3
domain-containing protein 19 (SH319), and T-complex protein 1 subunit beta (TCPB) were lower in patients with major
depression than in healthy controls.
Conclusions: Platelet provided valuable information about the pathways and processes of inflammation/immunity,
oxidative stress, and neurogenesis, related to major depression.
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Several theories have been proposed regarding the patho-
genesis of major depression, including the monoamine
theory of norepinephrine and serotonin (5-HT), systemic
immune activation, and neuroplasticity regulation of
brain-derived neurotrophic factors (BDNF). In addition,
the role of tissue-type plasminogen activators has also
been linked to BDNF from the viewpoint of platelets
[1-7], which are related to BDNF and serotonin release
[8,9]. Furthermore, many papers have discussed the role
of platelet activation in the psychopathology of major
depression [10-14].
In our previous study, we developed a technique combin-
ing acid hydrolysis with matrix-assisted laser desorption/
ionization time-of-flight mass spectrometry (MALDI-TOF
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reproduction in any medium, provided the orpositive and negative acute phase protein biomarkers in pa-
tients with major depression. The results suggested that pa-
tients with major depression had an increased level of
fibrinogen or a decreased level of transferrin [15]. These
molecules were related to the platelets.
MALDI-TOF mass spectrometers are extremely sensi-
tive instruments and have now been accepted as a major
analytical tool for the detection, identification, and
characterization of large biomolecules [16-18]. Two-
dimensional differential gel electrophoresis (2D-DIGE)
using CyDye DIGE Fluor minimal dyes has also been
established and used for studying the differential ex-
pression of proteins [19,20].
A recent review has deeply elucidated that a bidirectional
relationship between major depression and cardiovascular
disorder (CVD), associated with shared inflammatory and
oxidative and nitrosative stress (IO&NS) pathways [21].
Lines of evidence showed that IFNγ, a Th-1-like cytokine
which production is increased in major depression [22], is a
significant factor in atherogenesis and coronary artery dis-
ease (CAD) [23]. The other pro-inflammatory cytokines
that are increased in depression and that plays a role inLtd. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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TNF-α [26,27]. The patients with major depression and
animal models of depression were accompanied by induc-
tion of IO&NS pathways. The radical oxygen (ROS) and
nitrogen species (RNS) production, demonstrated by in-
crease levels of peroxide [28], nitric oxide (NO) produc-
tions [29,30] and xanthine oxidase (XO) activity [31] that
may react with fatty acid, proteins and DNA, and caused
damage.
Recent studies demonstrate that BDNF [32,33], neuro-
trophin-3 (NT-3) [34], glial cell line-derived neurotrophic
factor (GDNF) [35], fibroblast growth factor-2 (FGF-2)
[36] and nerve growth factor (NGF) [37] influence adult
hippocampal neurogenesis and regulate synaptic plasticity
in neuronal networks involved in major depression. Fur-
thermore, BDNF signaling was found to be associated with
phosphoinositol dependent kinase 3, Akt and glycogen
synthase kinase (GSK3) pathways [38-40].
It remains unclear that differences of the platelet pro-
tein between patients with major depression and healthy
controls. Therefore, in the present study, we attempted
to use the proteomic methods of 2D-DIGE, MALDI-
TOF MS, Western blot and bioinformatic tools to com-
pare the platelet protein profile between patients with
major depression and healthy controls.
Results
This study recruited 10 patients (mean age = 37.2
(+/− 9.3) years; mean body mass index = 24.2 (7.0) kg/m2;
female/male = 6:4) and 10 healthy controls (mean age = 33.1
(+/− 6.3) years; mean body mass index = 22.8 (2.7) kg/m2;
female/male = 6:4). The relative increase of at least 1.5-fold
in the abundance of protein spots in normal and patient
samples is shown in Table 1. The items include mascot
score, protein ID, accession number, protein name, Mr/PI
and sequence coverage. Moreover, all matched andTable 1 Relative changes in the abundance of different prote
patient samples
Spot no. Mascot score ID Accession no. Prot
H3(872) 88 FIBB P02675 Fibri
H4(867) 62 FIBB P02675 Fibri
H6(1026) 72 FIBB P02675 Fibri
H7(1023) 114 TCPB P78371 T-co
G11(1014) 57 FIBG P02679 Fibri
G13(1534) 63 SH319 Q5HYK7 SH3
G15(812) 61 RARB P10826 Retin
H16(1572) 57 GPX1 P07203 Gluta
G1(791) 86 PDIA3 P30101 Prote
H2(786) 94 PDIA3 P30101 Prote
G14(1317) 70 CAPZB P47756 F-act
SC: sequence coverage.unmatched masses, the matched peptide sequences infor-
mation, enzyme cleavage specificity, any modification and
deviations were provided in the Additional file 1: Table S1.
Eight proteins were identified among the patients with
major depression in the acute phase and healthy controls
(Figure 1). The levels of protein disulfide-isomerase A3
(PDIA3) and F-actin-capping protein subunit beta
(CAPZB) were higher in patients with major depression
than in healthy controls. The levels of 6 proteins, fibrino-
gen beta chain (FIBB), fibrinogen gamma chain (FIBG),
retinoic acid receptor beta (RARB), glutathione peroxidase
1 (GPX1), SH3 domain-containing protein 19 (SH319),
and T-complex protein 1 subunit beta (TCPB) were lower
in patients with major depression than in healthy controls.
However, because of the limited platelet amounts, only
7 patients and 7 controls (age- and sex-matched) were ex-
amined for protein validation by western blot analysis.
Among the identified proteins, protein disulfide-isomerase
A3 (PDIA3), fibrinogen beta chain (FIBB), glutathione per-
oxidase 1 (GPX-1), and retinoic acid receptor beta (RARB)
were validated by western blotting. The results are shown
in Figure 2. PDIA3 was up-regulated in the patients,
whereas FGB, GPX-1, and RARB were down-regulated in
the patients. Protein levels were quantified by densitomet-
ric analysis with the control being set at 1. Data presented
as means ± SD of three independent experiments for each
sample. The GPX1, FIBB and RARB were 0.66 ± 0.15,
0.45 ± 0.12 and 0.68 ± 0.17, respectively. The PDIA3 was
1.96 ± 0.39. The western blot analysis results of these 4 dif-
ferentially expressed proteins were in agreement with the
2-D PAGE expression data.
We used bioinformatic tools to classify these eight sig-
nificantly differential display proteins. The identified pro-
teins were mainly distributed in the cytoplasm, followed
by nucleus and secreted form (Table 2). The protein
SH319 and RARB located in the nucleus, but FIBB andin spots with at least 1.5-fold in control and
ein name Mr/PI SC Description
nogen beta chain 55/8.5 35 N>P
nogen beta chain 55/8.5 26 N>P
nogen beta chain 55/8.5 29 N>P
mplex protein 1 subunit beta 57/6.0 41 N>P
nogen gamma chain 51/5.3 18 N>P
domain-containing protein 19 86/8.5 11 N>P
oic acid receptor beta 50/8.0 11 N>P
thione peroxidase 1 21/6.1 23 N>P
in disulfdte-isomerase A3 56/5.9 25 P>N
in disulfide-isomerase A3 56/5.9 30 P>N
in-capping protein subunit beta 31/5.3 26 P>N
Figure 1 Representative overlapping 2D-DIGE expression maps of platelet proteins labeled with fluorescent dyes (Cy2, Cy3, and Cy5).
The 2D-DIGE overlay image of protein spots compares a healthy control sample labeled with Cy3 (green) to a patient sample labeled with Cy5
(red) and an internal standard sample common to all gels labeled with Cy2 (blue). This image is representative of 1of the 10 gels analyzed.
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Figure 2 Western blot analysis of human platelet proteins. Validation of PDIA3, FGB (FIBB), GPX1, and RARB. Nos. N1–N7 indicate healthy
control samples, and Nos. P1–P7 indicate patient samples.
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Table 2 Functional classification of differentially expressed
platelet proteins between healthy control and patients
with major depression by using BiNGO 2.44 software
Component Protein symbols*
Cytoplasm FIBB, FIBG, TCPB, GPX1,
FIBG, RARB, GPX1, PDIA3
Membrane-bound vesicle FIBG, PDIA3, FIBB
Stored secretory granule FIBG, FIBB
Nucleus SH319, RARB
Chaperone-containing T-complex TCPB
Molecular function
Protein binding FIBB, FIBG, TCPB, GPX1,
FIBG, RARB, GPX1, PDIA3
Cell surface binding FIBG, FIBB
Retinoic acid receptor activity RARB
Proline-rich region binding SH319
Intramolecular oxidoreductase activity PDIA3
Glutathione peroxidase activity GPX1
Biological process
Wound healing, response to metal ion FIBG, FIBB, GPX1
Positive regulation of cell death PDIA3, RARB, GPX1
Protein polymerization FIBG, FIBB
Muscle cell differentiation RARB, GPX1
Cell redox homeostasis PDIA3, GPX1
*FIBB: fibrinogen beta chain, TCPB: T-complex protein 1 subunit beta, GPX1:
glutathione peroxidase 1, FIBG: fibrinogen gamma chain, RARB: retinoic acid
receptor beta, PDIA3: protein disulfide-isomerase A3.
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and GO databases. Primary molecular function was bind-
ing and these identified proteins abundantly bind to pro-
tein, nucleotides, nucleic acid, receptor, chaperone and
actin (Table 2). The second molecular function was en-
zyme activity including retinoic acid receptor, transposing
S-S bonds and glutathione peroxidase (Table 2). Further
studies were performed to construct protein-protein inter-
action network and analyze correlation between disease
and identified proteins by the Metacore from GeneGo Inc.
Nodes with varied symbols stand for different types of pro-
teins and lines with different colors between nodes indicate
different protein-protein regulation modes. Moreover, we
put these eight identified protein together and tried to as-
semble protein-protein correlationships (Figure 3). There
are mainly two transcription factor, namely SP1 and AP-1
inclusive in the protein network. Other transcription factor
includes ERK1/2, c-Jun, c-Myc, c-Fos, RelA, HSF1, Elk-1,
STAT3, NF-κB, Oct-3/4 and SP3. The membrane receptors
primarily are integrin family (alpha 2, alpha 4, beta1, alpha
4/beta 1, alpha 5/beta 1, alpha 5/beta 3), Plexin A1, Throm-
bomodulin, Tissue factor.
The SH319 and PDIA3 seem to be excluded; however,
both of them were indirectly related to SP1. The SH319and SP1 activate a disintegrin and metalloprotease domain
17 (ADAM 17), as a tumor necrosis factor-alpha convert-
ing enzyme (TNF-alpha converting enzyme, TACE); binds
mitotic arrest deficient 2 protein; and also involves in the
activation of the Notch signaling pathway. The PDIA3 ac-
tivate calreticulin (molecular calcium-binding chaperone)
to hamper the binding of androgen receptor to its
hormone-responsive DNA element and inhibit retinoic
acid receptor transcriptional activities in vivo. The PDIA3
and SP1 activate MMP-9 to degrade collagen IV & V and
fibronectin. The PDIA3 could also activate immune sys-
tem through binding to MHC I for peptide antigen pres-
entation and processing.
The eight identified proteins could be related to some
disease developments according to Metacore database.
Table 3 shows that skin and connective tissue diseases,
breast neoplasms, pathologic processes, cardiovascular
diseases, neuroectodermal tumors, neuroepithelial neo-
plasms, kidney diseases, wounds and injuries, and cere-
brovascular disorders are associated with the identified
proteins. The disease target proteins consist of FIBB,
TCPB, GPX1, FIBG, RARB, and PDIA3. Among them,
GPX1 and fibrinogen play ultimately crucial roles serv-
ing as biomarkers for multiple diseases.Discussion
The most interesting finding in this study was higher
PDIA3 expression and lower FGB, GPX-1, and RARB
expression in patients with major depression than in
healthy controls. Moreover, these proteins were validated
by western blot.
PDIA3 is also known as a glucose-regulated protein; it
is an isomerase enzyme with a molecular mass of
58 kDa and is essential for the formation of the final
antigen conformation and exportation from the endo-
plasmic reticulum to the cell surface [41-43]. Data re-
garding the relationship between PDIA3 and major
depression are scarce. Previous studies showed that the
pharmacological actions of antidepressant drugs most af-
fected the metabolism of two neurotransmitters: sero-
tonin and noradrenaline. However, many aspects of
antidepressant action are not yet understood. McHugh
et al. [44] used a proteomic analysis in a neuronal cell
culture model to identify new molecules relevant to anti-
depressant action [44]. After antidepressant exposure,
they observed increased expression of PDIA3, sepiap-
terin reductase (SPR), and heat shock protein and de-
creased expression of creatine kinase, a T-cell receptor
alpha chain, defensin-related cryptdin 5, and the inter-
mediate filament protein glial fibrillary acidic protein.
Therefore, PDIA3, SPR, and the other proteins identified
might provide a link to the possible psychopathology of
major depression.
Protein-of-interest
Generic binding protein
Receptor ligand
Generic receptor
Ligand-gated ion channel
Protein
Generic enzyme
Protein kinase
Transcription factor
Figure 3 Networking construction of eight differentially expressed platelet proteins between healthy controls and patients with major
depression using Metacore software from GeneGo Inc.
Table 3 Correlationship between diseases and eight
differentially expressed platelet proteins between
healthy controls and patients with major depression
using Metacore software from GeneGo Inc
Disease Protein symbols*
Skin and connective tissue diseases FIBB, TCPB, GPX1, FIBG, RARB
Breast Neoplasms FIBB, TCPB, GPX1, FIBG, RARB
Pathologic processes FIBB, GPX1, FIBG, RARB
Cardiovascular diseases FIBB, GPX1, FIBG, RARB, PDIA3
Neuroectodermal tumors FIBB, GPX1, FIBG, RARB, PDIA3
Neoplasms, neuroepithelial GPX1, RARB, PDIA3
Glioma GPX1, RARB, PDIA3
Kidney diseases FIBB, GPX1, FIBG, RARB
Cerebrovascular disorders FIBB, GPX1, FIBG
Wounds and injuries FIBB, GPX1, FIBG
*FIBB: fibrinogen beta chain, TCPB: T-complex protein 1 subunit beta, GPX1:
glutathione peroxidase 1, FIBG: fibrinogen gamma chain, RARB: retinoic acid
receptor beta, PDIA3: protein disulfide-isomerase A3.
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lationship between inflammation and depression. The
blood markers of inflammation, including myeloperoxidase
(MPO), interleukin-6, white blood cell count, C-reactive
protein, tumor necrosis factor (TNF)-alpha, and fibrinogen,
were noted [45,46]. Vaccarino et al. [45] showed a strong
association of MPO and weaker association of other inflam-
matory biomarkers with major depression [45]. In addition,
Danese et al. [46] showed that in patients with a history of
childhood maltreatment, depression was associated with
high levels of high-sensitivity C-reactive protein [46]. On
the other hand, Markovitz et al. [47] found that depressed
patients had greater platelet secretion than the comparison
subjects in response to collagen; further, platelet secretion
in response to collagen was significantly reduced after treat-
ment with sertraline, an antidepressant [47]. Furthermore,
several studies have attempted to establish relationships
between fibrinogen, platelet, serotonin, BDNF, and major
depression [8-10].
With regard to GPX1, there is some evidence that the
activation of the immune-inflammatory process, increase
in monoamine catabolism, and abnormalities in lipid com-
pounds may cause overproduction of reactive oxygen spe-
cies (ROS) and, in turn, antioxidative enzyme activities
(AEAs) and lipid peroxidation (LP). These phenomena
may subsequently be related to the pathophysiology of
major depression. The antioxidant enzymes include
superoxide dismutase (SOD), catalase, and glutathioneperoxidase (GPX) and beta-adrenergic receptors [48,49].
Bilici et al. [48] showed that patients with major depres-
sion, especially melancholic patients, had higher AEA and
LP levels than those of healthy controls. After treatment
for 3 months with antidepressants, AEA and LP levels of
the patients significantly decreased to normal levels [48].
Although there was a decrease in nitrite content and beta-
adrenergic receptor binding in the patients with major
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the activities of SOD, catalase, and GPX were not signifi-
cantly altered in these patients [49]. However, major de-
pression induced the increased risk for cardiovascular
disorder (CVD) partially by significantly lower blood con-
centrations of major antioxidants and their enzyme activ-
ities as GPX [28,50]. Lang et al. [51] review molecular
mechanisms of depression and search for perspectives on
antidepressant treatment strategies [51].
With regard to RARB, several studies have recently
shown that the molecular components required for retin-
oic acid signaling are expressed in the adult brain [52-54].
The overlap of brain areas implicated in retinoic acid
function and stress and depression suggest that retinoids
could play a role in affective disorders. Retinoids represent
a family of compounds derived from vitamin A that per-
form a large number of functions, many via the vitamin A
derivative retinoic acid. This signaling molecule binds to
specific retinoic acid receptors in the brain, which, like the
glucocorticoid and thyroid hormone receptors, are part of
the nuclear receptor superfamily and regulate gene tran-
scription [52]. An examination of vitamin-deprived animals
revealed a progressive and ultimately profound impairment
of hippocampal CA1 long-term potentiation. Importantly,
these losses are fully reversible by dietary vitamin A replen-
ishment in vivo or direct application of all trans-retinoic
acids to acute hippocampal slices [53]. In a human study,
Chen et al. [54] showed that retinoic acid receptors (RAR)
might contribute to regulate the activity of corticotropin-
releasing hormone (CRH) neurons in vivo, and the vulner-
able characteristic of the critical proteins in the retinoic
acid (RA) signaling pathways might provide novel targets
for therapeutic strategies for depression [54]. In addition,
Katsuki et al. [55] revealed that RAR stimulation protects
midbrain dopaminergic neurons from inflammatory degen-
eration via BDNF-mediated signaling [55]. Further, cyclin-
dependent kinase 5 (CDK5) might influence the formation
of memory and mood by affecting differential effects of
glucocorticoid on BDNF expression [56]. These results also
indicate that neuroplasticity should be involved in the psy-
chopathology of major depression. The limitation of this
study was that a wash-out period of 1 week is very short.
The antidepressants included paroxetine 20 /day (n = 3),
Venlafaxine 150 mg/day (n = 2), Mirtazapine 60 mg/day
(n = 2) and drug naïve (n = 3) in this study. We could not
ascertain that there was has no effect on their results of
the drug state of the patients.
Conclusions
These findings suggest that the processes of inflamma-
tion/immunity, oxidative stress, and neurogenesis are in-
volved in the psychopathology of major depression. These
biomarkers infer the shared inflammatory and oxidative
and nitrosative stress pathways that may contribute tomajor depression and result in cardiovascular disorders. To
our knowledge, this is the first study to investigate the
platelet proteins of major depressive patients by using 2D-
DIGE, MALDI-TOF MS, and bioinformatic analyses. How-
ever, these data represent only preliminary results, and a
large sample is needed to prove these results. In addition,
the detailed functions of platelets in major depression need
to be further studied in the future.
Methods
Patients with major depression and healthy controls
This study was conducted from December 2007 to
November 2008 at Chang Gung Memorial Hospital
(CGMH)–Kaohsiung Medical Center, Taiwan. The
CGMH Ethics Committee formally issued an approval
for this study. Patients suffering from major depression
and healthy controls were selected according to the re-
sults of a Structured Clinical Interview for DSM-IV
Axis I Disorders (SCID) [57]. Patients with other co-
morbid psychiatric disorders should be excluded, in-
cluding bipolar disorder, schizophrenia, chronic fatigue
syndrome and fibromyalgia. All the participants were
free of liver, lung, renal, and metabolic diseases, and
they did not take any medication for at least 1 week
prior to entering this study.
Separation of platelets from blood
Blood sample was collected into 1.5 eppendorf tubes;
thereafter, 100 μl of ACD (acid-citrate-dextrose; Sigma C-
3821), 300 μl of blood, and 660 μl of NaN3/PBS (0.05%)
were centrifuged at 250 g for 10 min at 10°C. The super-
natant was added to a new eppendorf tube and centrifuged
at 1613 g for 10 min at 10°C. Next, the supernatant was
discarded, and the platelets were washed in 1 ml of NaN3/
PBS (0.05%). Thereafter, the platelets were centrifuged at
1613 g for 10 min at 10°C. After the supernatant was dis-
carded, 200 μl of lysis buffer (8 M urea, 4% CHAPS,
30 mM Tris-Cl, pH 8.5) was added to the platelets, and
they were stored at -80°C.
2D-DIGE analysis of the platelets
Total protein was quantified in 10 pooled control samples
and 10 pooled patient samples using the Bio-Rad protein
assay. The platelet proteins were then concentrated, and
impurities removed using the 2D Clean Up Kit. The final
precipitated pellets were redissolved in 60 μl of lysis buffer
(8 M urea, 4% CHAPS, 30 mM Tris-Cl, pH 8.5), the total
protein was quantified again, and the samples were stored
on ice prior to subsequent Cy dye labeling. Each sample
was labeled with 200 pmol (1 μl) of Cy dye per 50 μg of
protein, incubated on ice for 30 min in the dark, and
quenched with 1 μl of 10 mM lysine; each sample was
then incubated on ice for 10 min in the dark, according to
the manufacturer’s protocol. Ten control and 10 patient
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with either Cy3 or Cy5, and the internal standard (200 μg
of protein comprising 25 μg from each of the 20 samples)
was labeled with Cy2. One standard, control, and patient
sample forming a set of Cy2-, Cy3-, and Cy5-labeled sam-
ples was combined for each of 10 gels and mixed with re-
hydration buffer (8 M urea, 1% CHAPS, 0.5% ASB14,
65 mM DTT, 0.5% v/v pharmalytes pH 3–10, 0.005% bro-
mophenol blue) to a total volume of 250 μl per gel. The
first dimension separation was performed on an IPGphor
isoelectric focusing (IEF) unit (GE Healthcare) by applying
combined samples to immobilized pH gradient (IPG)
13-cm pH 4–7 strips with rehydration at 30 V for 16 h
followed by isoelectric focusing at 500 V for 1 h, 1000 V
gradient for 1 h, and then 8000 V step for 32,000 V/h, for
a total of 6 h and 30 V. Strips were each immediately
equilibrated in a 5 ml solution of 6 M urea, 30% glycerol,
2% SDS, 75 mM Tris-Cl (pH 8.8), and 0.005% bromophe-
nol blue for 15 min with 1% (w/v) DTT and subsequently
for 15 min with 2.5% (w/v) iodoacetamide (IAA). A mo-
lecular weight marker (17–170 kDa) was added to one gel
for reference. For the second dimension, strips were ap-
plied directly to 10% SDS-polyacrylamide gels, and 4 gels
were run simultaneously on a SE600 (GE Healthcare)
electrophoresis unit at 10°C at 0.35 W/gel for 16 h. Im-
mediately after 2D-DIGE, the gels were scanned with a
Typhoon Trio imager using an excitation/emission filter
of 488/520 nm for Cy2, 532/580 nm for Cy3, and 633/
670 nm for Cy5 to generate multiplexed DIGE image
files. Statistical and quantitative analyses of the spot
changes on the images were completed using DeCyder
software (GE Healthcare).In-gel digestion and protein identification
Protein spots were excised from the gel, and the gel was
washed 3 times with 200 μl H2O for 5 min by vortexing.
The supernatant was discarded, and 200 μl of destaining
agent (0.1 g K3Fe(CN)6 and 0.16 g Na2S2O3 in 10 ml dd
H2O) were added by vortexing for 15 min. The super-
natant was again discarded, and the gel was washed 3
times in 200 μl of washing solution I [50 mM NH4HCO3/
100% ACN (3:2)] by vortexing for 15 min. The super-
natant was discarded, and 200 μl of 100% ACN was added
by vortexing for 10 min. Then, the supernatant was dis-
carded, with a vacuum centrifuge for 10 min at room
temperature (RT). After adding 6–8 μl of trypsin buffer
(25 ng/μl trypsin, 25 mM NH4HCO) to cover the gels, the
gels were digested in trypsin solution for 16 h at 37°C. The
peptides obtained were extracted from the gel with extrac-
tion buffer (100% acetonitrile, 1% trifluoroacetic acid),
concentrated with a vacuum centrifuge for 10 min at
room temperature (RT), and rehydrated by the addition of
10 μl of deionized water.Before their MS spectra and MS/MS fragment ion
mass were determined with a Bruker MALDI-TOF/
TOF Analyzer (Bruker Daltonics, Bremen, Germany),
all product ions were submitted to a computer database
search analysis with the Mascot MS/MS ion search
(Matrix Science Inc., MA) by using the SwissProt data-
base (all entries). The Bruker operation system, namely
flexControl Version 3.3 (Build 85) and flexAnalysis soft-
ware were used to create peak lists.
MALDI-TOF/TOF data were searched in-house MAS-
COT software (ver 2.2.04). The following parameters were
used: enzyme, trypsin; variable modification, carbamido-
methyl and oxidation; mass values, monoisotopic; peptide
mass tolerance, ±100 ppm; peptide charge state, 1+; max-
imum missed cleavage, 1; significance threshold, p < 0.05.
Peptide identification and protein assembly were per-
formed in multiple stages. The protein identifications re-
quired detection of unique peptides and proteins with
more than two spectral counts were selected for further
analysis. The peptide mass data of each spot was submit-
ted to the Swiss-Prot 100425 human species bioinforma-
tion stations using MASCOT search engines. Proteins
identified with a higher MASCOT score in the bovine
database than in the human database were considered as
serum contamination and removed.
Validation by western blotting and statistical analyses
The data of the platelet proteins were analyzed using
DeCyder software (P < 0.05 in t-test; ratio of patient/nor-
mal >1.5 or <1.5) in 10 patient and 10 control samples.
However, because of the limited amount of platelets, only
7 patients and 7 controls (age and sex matched) were ex-
amined for protein validation by western blot analysis.
Protein levels were quantified by densitometric analysis
with the healthy control being set at 1. Data presented
as means ± SD of three independent experiments for
each sample.Bioinformatic tools for protein searches and
networking construction
The protein search programs used the following databases:
NCBI (http://www.ncbi.nlm.nih.gov), and UniProtKB/Swiss-
Prot (http://www.uniprot.org/). In addition, the functional
protein association networks or protein interactions were
searched by STRING database (http://string-db.org/). The
combining pathway databases of BioCarta (http://www.bio-
carta.com/genes/index.asp), KEGG (http://www.genome.jp/
kegg/pathway.html) and the PubMed literature (http://www.
ncbi.nlm.nih.gov/pubmed/) were also used to search the
correlated regulatory pathways in major depression and
other related reactions. The MetaCore from GeneGo Inc.
(Version 6.5) was applied in thoroughly compiling protein
functional classification and interaction networks.
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using Mascot software (ver 2.2.04).
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